Findings

What do systematic reviews say?

6 questions · 6 findings · 1 reviews · Skin

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 4 · 66.7%Low 2 · 33.3%Moderate 0 · 0%High 0 · 0%

Potent vs mild‐potency topical corticosteroid

Local adverse events: skin thinning; end of treatment (16‐20 weeks + 2‐4 weeks acute phase) · children and adults with mild to severe eczema

1 finding from 1 review

Strategies for using topical corticosteroids in children and adults with eczema 2022 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 440 participants
Low

Potent vs moderate‐potency topical corticosteroid

Local adverse events: skin thinning; end of treatment (1 to 3 weeks) · children and adults, most with moderate to severe eczema

1 finding from 1 review

Strategies for using topical corticosteroids in children and adults with eczema 2022 · Cochrane Headline outcomes only
no estimate extracted
10 studies · 541 participants
Low

Potent vs mild‐potency topical corticosteroid

Systemic adverse events: abnormal cortisol; end of treatment (1‐6 weeks) · children and adults with mild to severe eczema

1 finding from 1 review

Strategies for using topical corticosteroids in children and adults with eczema 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 82 participants
Very low

Potent vs moderate‐potency topical corticosteroid

Systemic adverse events: abnormal cortisol; end of treatment (1‐6 weeks) · children and adults, most with moderate to severe eczema

1 finding from 1 review

Strategies for using topical corticosteroids in children and adults with eczema 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 99 participants
Very low

Very potent vs potent topical corticosteroid

Systemic adverse events: abnormal cortisol · adults with eczema

1 finding from 1 review

Strategies for using topical corticosteroids in children and adults with eczema 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 117 participants
Very low

Very potent vs potent topical corticosteroid

Local adverse events: skin thinning; end of treatment (1 to 3 weeks) · adults with eczema

It is very uncertain whether very potent changes local adverse events: skin thinning; end of treatment (day 11‐day 22) compared with potent topical corticosteroid (very low certainty).

1 finding from 1 review

Strategies for using topical corticosteroids in children and adults with eczema 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 233 participants
Very low